Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-29
2008-07-29
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S275000, C544S309000, C544S310000, C544S323000, C544S324000
Reexamination Certificate
active
07405221
ABSTRACT:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver
REFERENCES:
patent: 4438117 (1984-03-01), Cherkofsky
patent: 5366982 (1994-11-01), Dereu et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5684011 (1997-11-01), Fitzjohn et al.
patent: 6096753 (2000-08-01), Spohr et al.
patent: 2002/0004600 (2002-01-01), Meyer et al.
patent: 2004/0259887 (2004-12-01), Dow
patent: 2005/0043315 (2005-02-01), Tsutsumi et al.
patent: 0 576 357 (1997-03-01), None
patent: 0 656 354 (1997-06-01), None
patent: WO 98/32441 (1998-07-01), None
patent: WO 98/37061 (1998-08-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 03/002114 (2003-01-01), None
patent: WO 03/006007 (2003-01-01), None
patent: WO 03/000787 (2003-03-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/051850 (2003-06-01), None
patent: WO 03/051851 (2003-06-01), None
patent: WO 03/084935 (2003-10-01), None
patent: WO 03/084943 (2003-10-01), None
patent: WO 2004009560 (2004-01-01), None
patent: WO 2004/012671 (2004-02-01), None
patent: WO 2004016605 (2004-02-01), None
patent: WO 2004/018433 (2004-03-01), None
patent: WO 2004/035566 (2004-04-01), None
patent: WO 2004/037823 (2004-05-01), None
patent: WO 2004/052864 (2004-06-01), None
patent: WO 2004/094421 (2004-11-01), None
patent: WO 2004/105699 (2004-12-01), None
patent: WO 2004/110453 (2004-12-01), None
patent: WO 2004/111033 (2004-12-01), None
patent: WO 2004/111034 (2004-12-01), None
patent: WO 2004/111038 (2004-12-01), None
patent: WO 2004/111039 (2004-12-01), None
patent: WO 2005/000817 (2005-01-01), None
patent: WO 2005/009479 (2005-02-01), None
patent: WO 2005/016286 (2005-02-01), None
patent: WO 2005/020992 (2005-03-01), None
Petrocellis et al., British Journal of Pharmacology, 141, 765-774, 2004.
Black, Curr. Opin.. Investig. Drugs 5(4): 389-394, 2004.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Olivera et al., Tetrahedron 58(15):3021-3037, 2002.
Gaodeng Xuexiao Huaxue Xuebao 16(11): 1740-1743, 1995. CA 124: 317095,1996.
DD 294255, CA 116: 128952,1992.
Chemistry of Natural Compounds (Translation of Khimya Prirodnykh Soedinenii) 37(4): 307-310, 2001, CA 137: 78805, 2002.
Khimya Geterotsiklicheskikh Soedinenii, 11: 1542-1550, 1985, CA 105: 208819, 1986.
Tanaka et al., Chemical & Pharmaceutical Bulletin 42(9), 1828-1834, 1994; CA123:9410, 1995.
Le Foll et al., J. Pharm. & Exper. Ther., vol. 312 (2005), pp. 875-883, “Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence”.
Lange et al., J. Med. Chem., Bioisosteric replacements of the pyrazole moiety of rimonabant . . . 48(6), 1823-1839, 2005.
Piomelli et al., Trends in Pharma. Sci., vol. 21 (2000), pp. 218-224, “The endocannabinoid system as a target for therapeutic drugs”.
Goya et al., Exp. Opin. Ther. Patents, vol. 10 (2000), pp. 1529-1538, “Recent advances in cannabinoid receptor agonists and antagonists”.
Xiang et al., Ann. Reports in Med. Chem., vol. 34 (1999), pp. 199-208, “Chap. 20. Pharmacology of cannabinoid receptor agonists and antagonists”.
Barth, Exp. Opin. Ther. Patents, vol. 8 (1998), pp. 301-313, “Cannabinoid receptor agonists and antagonists”.
Rinaldi-Carmona et al., Life Sciences, vol. 56 (1995), pp. 1941-1947, “Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist”.
Rinaldi-Carmona et al., FEBS Letters, vol. 350 (1994), pp. 250-244, “SR141716A, a potent and selective antagonist of the brain cannabinoid receptor”.
Hetzheim et al., Pharmazie, vol. 40(1) (1985), pp. 17-20, “Ringtransformation von O,N-heterocyclen”.
Hagmann William K.
Kopka Ihor E.
Li Bing
Balasubramanian Venkataraman
Brown Baerbel R.
Fitch Catherine D.
Merck & Co. , Inc.
LandOfFree
Substituted pyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrimidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2777903